Literature DB >> 22869868

Aflibercept in pediatric solid tumors: moving beyond the trap.

Cindy H Chau1, William D Figg.   

Abstract

Angiogenesis plays a pivotal role in the growth and metastasis of adult and pediatric solid tumors. Clinical investigation of angiogenesis inhibitors is currently under way for childhood cancers. While the pediatric study of aflibercept provides a proof-of-principle, challenges remain in developing clinical endpoints and biomarkers of angiogenesis for pediatric trials. ©2012 AACR. V

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22869868      PMCID： PMC3445740          DOI： 10.1158/1078-0432.CCR-12-2212

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

Review 1.  Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.

Authors:  Vishal Ranpura; Sanjaykumar Hapani; Shenhong Wu
Journal:  JAMA       Date:  2011-02-02       Impact factor: 56.272

Review 2.  A preclinical and clinical review of aflibercept for the management of cancer.

Authors:  Andrew Gaya; Vivien Tse
Journal:  Cancer Treat Rev       Date:  2012-01-20       Impact factor: 12.111

Review 3.  Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.

Authors:  Julia Glade Bender; Darrell J Yamashiro; Elizabeth Fox
Journal:  Oncologist       Date:  2011-10-31

4.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

5.  Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.

Authors:  Julia L Glade Bender; Peter C Adamson; Joel M Reid; Lu Xu; Sylvain Baruchel; Yuval Shaked; Robert S Kerbel; Erin M Cooney-Qualter; Diana Stempak; Helen X Chen; Marvin D Nelson; Mark D Krailo; Ashish M Ingle; Susan M Blaney; Jessica J Kandel; Darrell J Yamashiro
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

6.  Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

Authors:  A Craig Lockhart; Mace L Rothenberg; Jakob Dupont; Wendy Cooper; Paul Chevalier; Lars Sternas; Giliane Buzenet; Elizabeth Koehler; Jeffrey A Sosman; Lawrence H Schwartz; David H Gultekin; Jason A Koutcher; Edwin F Donnelly; Ric Andal; Isabelle Dancy; David R Spriggs; William P Tew
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

7.  VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.

Authors:  John S Rudge; Jocelyn Holash; Donna Hylton; Michelle Russell; Shelly Jiang; Raymond Leidich; Nicholas Papadopoulos; Erica A Pyles; Al Torri; Stanley J Wiegand; Gavin Thurston; Neil Stahl; George D Yancopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

Review 8.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

Authors:  Christian Fischer; Massimiliano Mazzone; Bart Jonckx; Peter Carmeliet
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

9.  A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.

Authors:  Julia Glade Bender; Susan M Blaney; Scott Borinstein; Joel M Reid; Sylvain Baruchel; Charlotte Ahern; Ashish M Ingle; Darrell J Yamashiro; Alice Chen; Brenda Weigel; Peter C Adamson; Julie R Park
Journal:  Clin Cancer Res       Date:  2012-07-12       Impact factor: 12.531

10.  Isolation of a tumor factor responsible for angiogenesis.

Authors:  J Folkman; E Merler; C Abernathy; G Williams
Journal:  J Exp Med       Date:  1971-02-01       Impact factor: 14.307
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.